What were the drivers for targeting investment dollars into frontier science? We consider our companies are rewriting the physical layer around us. When you apply computation to biology and chemistry, it redefines what’s possible in these major industries like medicine, agriculture and chemicals. In parallel, we have high-powered computation and data science that’s grown up at the same time as sequencing and has become nearly freely available. Genetic sequencing is enabling us to understand the DNA/RNA that’s driving cells all around us - in plants, humans and microbes. McClary: We are on the verge of a biological revolution, meaning all of sudden, we now have the source code to the physical layer around us. Not many people are familiar with the term “frontier science.” What does it mean to you? We are looking at funding approximately 25 companies in Fund II. We’re in a position to elevate impactful science at the earliest stages because there are not many science VCs at the seed stage. McClary: Now that we have finished raising, we have plans to increase the check size to between $700,000 and $1 million per check for pre-seed or seed-stage rounds. What is your target for Fund II? KdT’s founder and Managing Partner Cain McClary. The following was lightly edited for clarity and length. I spoke to KdT’s founder and Managing Partner Cain McClary and Principal Rima Chakrabarti to help us better understand what exactly “frontier science” is and how it will change the world. KdT already started deploying capital from the new fund into companies, including Elegen, Xilis, Abridge, Dimension Inx and Andes. The new fund will target companies in areas such as gene and biological circuit fabrication, novel delivery technologies, biomaterials innovation and consumer biology. With its first fund, the firm made 18 investments in companies, including PathAI, 54gene and Checkerspot. This is KdT’s second fund, following a $15 million inaugural fund in 2017.
KdT Ventures, an early-stage venture capital firm based in Austin, closed its Fund II with an oversubscribed $50 million in dedicated investment to back companies focused on startups at the intersection of data, engineering and biology.
Strategy Session is a feature for Crunchbase News where we ask venture capital firms five questions about their investment strategies.
#Abridge crunchbase how to
Freelance Writers: How To Pitch Crunchbase News.
0 kommentar(er)
